FOLH1 and neoplasm: We evaluated the ligands in comparison with reference ligands [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA I&T (Fig. 2) in vitro (lipophilicity, half-maximal inhibitory concentration, internalization into LNCaP cells, binding to human serum albumin [HSA]) and in biodistribution studies on LNCaP tumor–bearing mice.